Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes
Open Access
- 15 February 2022
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 24 (6) , 1061-1071
Abstract
Aims: Empagliflozin treatment reduced liver fat in small type 2 diabetes cohorts. This post‐hoc study evaluated effects of empagliflozin on risk for non‐alcoholic fatty liver disease‐related steatosis and fibrosis, as well as the relationship between risk categories and cardiorenal outcomes in the randomized, placebo‐controlled EMPA‐REG OUTCOME trial. Materials and methods: EMPA‐REG OUTCOME treated 7020 people with type 2 diabetes and cardiovascular disease with 10/25 mg/day empagliflozin or placebo. For this analysis, the Dallas steatosis index, hepatic steatosis index, non‐alcoholic fatty liver disease fibrosis score and Fibrosis‐4 score were calculated to assess steatosis and fibrosis risk. Changes from baseline in scores were examined by mixed model repeated measures and their associations with cardiorenal outcomes and mortality by Cox regression. Results: At baseline, 73% and 84% of participants had high steatosis risk by Dallas steatosis index and hepatic steatosis index, whereas 23% and 4% had a high risk of advanced fibrosis by non‐alcoholic fatty liver disease fibrosis score and Fibrosis‐4 score. Percentages of people at high steatosis risk slightly decreased with empagliflozin only, whereas empagliflozin did not improve percentages of individuals at high fibrosis risk over time compared with placebo. The high risk of advanced fibrosis at baseline related to higher risk for cardiovascular events. Effects of empagliflozin on cardiorenal and all‐cause mortality outcomes were consistent across all risk groups. Conclusions: Empagliflozin may reduce steatosis but not fibrosis risk in individuals with type 2 diabetes and cardiovascular disease. The improvements in cardiorenal outcomes and mortality associated with empagliflozin therapy appear to be independent of steatosis and fibrosis risk.Keywords
Funding Information
- Boehringer Ingelheim
This publication has 26 references indexed in Scilit:
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver DiseasesHepatology, 2017
- Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy‐proven NASHLiver International, 2017
- NAFLD and diabetes mellitusNature Reviews Gastroenterology & Hepatology, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver diseaseAlimentary Pharmacology & Therapeutics, 2014
- Comparison of Liver Fat Indices for the Diagnosis of Hepatic Steatosis and Insulin ResistancePLOS ONE, 2014
- NAFLD fibrosis score: A prognostic predictor for mortality and liver complications among NAFLD patientsWorld Journal of Gastroenterology, 2013
- Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United StatesHepatology, 2012
- Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver diseaseDigestive and Liver Disease, 2010
- Evolution of hepatic steatosis in patients with advanced hepatitis CHepatology, 2009